Elsevier

The Lancet

Volume 358, Issue 9289, 13 October 2001, Pages 1239-1241
The Lancet

Research Letters
Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

https://doi.org/10.1016/S0140-6736(01)06355-3Get rights and content

Summary

Molecular monitoring by quantitative PCR techniques of residual leukaemia cells during the first phases of treatment can predict outcome in children with acute lymphoblastic leukaemia. We did a retrospective study of 30 children who had been treated according to the ALL-REZ BFM trials to assess whether amount of minimal residual disease during the first stages of treatment for relapsed acute lymphoblastic leukaemia could predict outcome. In children with minimal residual disease of less than 10−3 at day 36, probability of event-free survival was 0·86 (95% CI 0·77–0·95), compared with 0 in children with minimal residual disease of 10−3 or greater (p<0·001). Our results suggest that information about molecular response to treatment can be used to predict long-term outcome in relapsed childhood acute lymphoblastic leukaemia.

Cited by (192)

  • Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial

    2019, The Lancet Haematology
    Citation Excerpt :

    Irrespective of treatment strategies, children relapsing more than 6 months after stopping therapy have better survival rates than those who relapse earlier (overall survival 45–73% for those who relapse >6 months later vs 22–38% for those who relapse earlier),1–4 suggesting that recurring blasts remain chemosensitive in many patients. The BFM Study Group identified a subset of patients with late bone marrow relapses (isolated or combined) who had low minimal residual disease (defined as <10−3 cells) at end of induction and could thus be maintained in second complete remission with chemotherapy and targeted radiotherapy.5 Those with minimal residual disease comprising 10−3 cells or more, however, frequently had a second relapse.

  • Relapsed Acute Lymphoblastic Leukemia

    2024, Indian Journal of Pediatrics
View all citing articles on Scopus
View full text